Biogen Inc. BIIB said Tuesday it had net income of $387.9 million, or $2.67 a share, for the first quarter, up from $303.8 million, or $2.06 a share, in the year-earlier period. Adjusted per-share earnings came to $3.40, ahead of the $3.28 FactSet consensus. Revenue fell 3% to $2.463 billion from $2.532 billion, but also beat the $2.342 billion FactSet consensus. Sales of the company’s MS drugs fell 19% $1.125 billion, while sales of its spinal muscular atrophy treatments fell 6% to $443 million. Alzheimer’s disease revenue was a negative $18 million. The company is taking a 50% share of profit and losses for Leqembi…
